PMID- 22777758
OWN - NLM
STAT- MEDLINE
DCOM- 20130712
LR  - 20211021
IS  - 1613-6829 (Electronic)
IS  - 1613-6810 (Print)
IS  - 1613-6810 (Linking)
VI  - 8
IP  - 18
DP  - 2012 Sep 24
TI  - High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery.
PG  - 2895-903
LID - 10.1002/smll.201200437 [doi]
AB  - The in vitro and in vivo characterization of an optimized formulation of 
      nanoparticles (NPs) loaded with a high content of dexamethasone palmitate 
      (DEX-P), a chemotherapeutic adjuvant that decreases interstitial fluid pressure 
      in tumors, and (111) In, a signaling agent, is described. These NPs are uniform 
      in size and composition. Single photon emission computed tomography imaging 
      demonstrates significant tumor uptake of (111) In-labeled DEX-P NPs in 
      tumor-bearing mice. As with many nanoparticle-based drug delivery systems, 
      significant liver accumulation is observed. Assessment of liver histology and 
      blood tests show no apparent hepatic or renal toxicity of the DEX-P NPs. 
      Conversion of DEX-P to DEX occurs when DEX-P NPs are incubated with mouse plasma, 
      human tumor homogenate and ascites from tumor bearing mice, but not with human 
      plasma. This conversion is slower in plasma from Es1(e) ((-/-)) /SCID mice, a 
      potential alternative animal model that better mimics humans; however, plasma 
      from these mice are not completely devoid of esterase activity. The difference 
      between blood and tumor esterase activity in humans facilitates the delivery of 
      DEX-P NPs to tumors and the release of dexamethasone by an esterase trigger.
CI  - Copyright (c) 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Kim, Jin-Ki
AU  - Kim JK
AD  - Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, 
      Eshelman School of Pharmacy and Lineberger, Comprehensive Cancer Center, 
      University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, 
      USA.
FAU - Yuan, Hong
AU  - Yuan H
FAU - Nie, Jingxin
AU  - Nie J
FAU - Yang, Yu-Tsai
AU  - Yang YT
FAU - Leggas, Markos
AU  - Leggas M
FAU - Potter, Philip M
AU  - Potter PM
FAU - Rinehart, John
AU  - Rinehart J
FAU - Jay, Michael
AU  - Jay M
FAU - Lu, Xiuling
AU  - Lu X
LA  - eng
GR  - P30 CA021765/CA/NCI NIH HHS/United States
GR  - R01 CA108775/CA/NCI NIH HHS/United States
GR  - CA108775/CA/NCI NIH HHS/United States
GR  - CA21765/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120706
PL  - Germany
TA  - Small
JT  - Small (Weinheim an der Bergstrasse, Germany)
JID - 101235338
RN  - 0 (Drug Carriers)
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Prodrugs)
RN  - 0 (Radiopharmaceuticals)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Dexamethasone/administration & dosage/chemistry/*pharmacokinetics
MH  - *Drug Carriers
MH  - Female
MH  - Humans
MH  - Indium Radioisotopes
MH  - Mice
MH  - Mice, Nude
MH  - Mice, SCID
MH  - Nanoparticles/administration & dosage/*chemistry
MH  - Neoplasm Transplantation
MH  - Neoplasms/*diagnostic imaging/*drug therapy/metabolism
MH  - Prodrugs/administration & dosage/chemistry/*pharmacokinetics
MH  - Radiopharmaceuticals/administration & dosage/chemistry/*pharmacokinetics
MH  - Tomography, Emission-Computed, Single-Photon
MH  - Transplantation, Heterologous
PMC - PMC3817621
MID - NIHMS502284
EDAT- 2012/07/11 06:00
MHDA- 2013/07/16 06:00
PMCR- 2013/11/05
CRDT- 2012/07/11 06:00
PHST- 2012/02/27 00:00 [received]
PHST- 2012/04/17 00:00 [revised]
PHST- 2012/07/11 06:00 [entrez]
PHST- 2012/07/11 06:00 [pubmed]
PHST- 2013/07/16 06:00 [medline]
PHST- 2013/11/05 00:00 [pmc-release]
AID - 10.1002/smll.201200437 [doi]
PST - ppublish
SO  - Small. 2012 Sep 24;8(18):2895-903. doi: 10.1002/smll.201200437. Epub 2012 Jul 6.